Literature DB >> 7942735

Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C.

S Sugano1, M Yanagimoto, T Suzuki, M Sato, H Onmura, H Aizawa, H Makino.   

Abstract

Retinal hemorrhage is a complication of interferon therapy of unknown pathogenesis. We report two chronic active hepatitis C patients who developed retinal hemorrhage and/or cotton wool patches during interferon-alpha therapy 4 and 12 wk after beginning treatment. At the time of the hemorrhage, plasma-activated complement 5, a known potent intravascular aggregator of granulocytes, increased to 54 ng/ml in one patient and to 29 ng/ml in the other patient. When the hemorrhage resolved, it decreased to under 5 ng/ml. Our cases suggest that complement activation occurs in patients treated with interferon-alpha and that activation of complement 5 can lead to retinal capillary infarction and retinal hemorrhage. High levels of activated complement 5 may predict retinal artery infarction or perhaps microvascular emboli in the other organs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942735

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Bilateral juxtapapillary choroidal neovascularisation associated with interferon alfa treatment of a metastatic cutaneous melanoma.

Authors:  J Garcia-Arumi; M Morral Palau; M Montolio Gil; H Blasco Garrido; L Sararols Ramsay; A Segura García
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

2.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

Review 3.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 4.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

5.  Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.

Authors:  Jose G Monzon; Nazik Hammad; Samuel D Stevens; Janet Dancey
Journal:  Oncologist       Date:  2012-02-14

Review 6.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 7.  New roles for the major human 3'-5' exonuclease TREX1 in human disease.

Authors:  David Kavanagh; Dirk Spitzer; Parul H Kothari; Aisha Shaikh; M Kathryn Liszewski; Anna Richards; John P Atkinson
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

8.  Is screening for interferon retinopathy in hepatitis C justified?

Authors:  F M Cuthbertson; M Davies; M McKibbin
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

Review 9.  Treatment of hepatitis C virus infection and associated vascular complications: a literature review.

Authors:  Reza Karbasi-Afshar
Journal:  Iran J Med Sci       Date:  2014-05

10.  Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy.

Authors:  Fatih Selcukbiricik; Deniz Tural; Tuba Elif Senel; Ahmet Sarıca; Ozlem Soyluk; Suheyla Serdengecti
Journal:  Case Rep Ophthalmol Med       Date:  2012-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.